48-Week effectiveness and tolerability of dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-naïve adults living with HIV: A multicenter real-life cohortAlfonso Cabello, Miguel Górgolas, Francisco Tejerina et al.|PLoS ONE|2022Cited by 20
Antiretroviral treatment outcomes among late HIV presenters initiating treatment with integrase inhibitors or protease inhibitorsGundolf Schuettfort, AE Haberl, L Boekenkamp et al.|HIV Medicine|2020Cited by 15
Reasons for Choice of Antiretroviral Regimens in HIV Patients Presenting Late for Initial Treatment in EuropeGundolf Schuettfort, Annette E. Haberl, Alfonso Cabello et al.|AIDS Patient Care and STDs|2021Cited by 11
Recent infections among newly diagnosed cases of HIV infection in Spain, 2015–2016. National estimates using cohort dataVíctoria Hernando, María Teresa Cuevas, María Tasias et al.|Scandinavian Journal of Infectious Diseases|2021Cited by 2
Dolutegravir (DTG) + Lamivudine (3 TC) in Antiretroviral-Naive Adults With HIV With and Without Genotypic Resistance Testing Results: 96-Week Effectiveness and Tolerability of REDOLA StudyAlfonso Cabello, Federico Pulido, Juan Carlos López Bernardo de Quirós et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2025Cited by 1